Roche touts PhII win for BTK inhibitor in multiple sclerosis as PhIII showdown with Sanofi, Merck KGaA, Novartis looms
Roche is staking its claim in the race to develop a BTK inhibitor for multiple sclerosis, with a topline Phase II win showing its candidate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
